Parkinson's Patients' rhythm skills tested on and off medication
NCT ID NCT07647913
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how dopamine levels affect the ability to keep a steady beat in people with early-stage Parkinson's disease. 34 participants will do simple tapping tasks both on their usual levodopa medication and after skipping it for 12 hours. The goal is to understand whether dopamine helps shield rhythm skills from distractions and allows people to adapt to changing speeds.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Levodopa withdrawal (withholding medication)
- What this could lead to
- If successful, this could help design better music- or rhythm-based therapies for movement problems in Parkinson's.
- What could go wrong
- This is a small, early-stage study (34 people) that only looks at short-term effects. It won't directly test a new treatment, so benefits are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 34 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Parkinson's Disease diagnostic * Stage 1 or 2 Hoenh-Yahr scale * Taking immediate-release Levodopa * MoCA score of 26 or above Exclusion Criteria: * Dementia * Other neurodegenerative disease * History of substance abuse * History of hearing disorders * History of neuropsychiatric disease
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Parkinson disease (PD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Psychology Building
Hamilton, Ontario, L8S 4L8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Can focused electrical fields deep in the brain ease Parkinson's tremors?
- Vibrating wristband put to the test for Parkinson's relief
- Can a breathing and Nerve-Zapping combo help clear the Parkinson's brain?
- Can group brain training slow Parkinson's cognitive decline?
- Old drug showdown: can benzhexol match procyclidine for Parkinson's tremor?